DNA can be damaged due to endogenous factors (oxidation) or exogenous factors (UV radiations or viruses), but our cell can identify and repair the damage. However, when the repairing mechanism of the cell fails, it leads to dysfunctionality or mutations in the DNA of the cell. It can also lead to abnormal growth of cells, i.e., cancer. Such irreparable damage can be treated with DNA repair drugs such as poly ADP-ribose polymerase inhibitors (PARP). PARP blocks the activity of ADP-ribose polymerase proteins, thus preventing the replication of cancer cells.

 

Global DNA Repair Drugs Market Drivers

 

Increasing collaboration and acquisition activities are expected to boost the global DNA repair drugs market growth. For instance, in January 2017, Merck KGaA entered into a licensed agreement with Vertex Pharmaceuticals Inc., for four research developments on approaches to cancer. The reason for the partnership was to strengthen Merck’s area of DNA damage response and immuno-oncology. Furthermore, in February 2016, Onxeo, an orphan oncology therapeutics company, acquired DNA Therapeutics, a biopharmaceutical company for its DNA repairing technology for treatment of cancer. This technology consists of a signal interfering DNA molecule (siDNA), and Onxeo S.A. intends to develop this technology as a potential treatment option for cancer. Such partnerships are expected to propel the global DNA repair drugs market growth.

 

Global DNA Repair Drugs Market Regional Analysis

 

North America is expected to hold a dominant position in the global DNA repair drugs market. Factors such as increasing research and development activities are expected to have an influence on the North America’s DNA repair drugs market growth. For instance, in 2017, Harvard Medical School and University of South Wales conducted a study on DNA repair drugs for treatment of radiation damage that causes cancer. They have discovered the mechanism that weakens the system of our cell’s capability to repair the damages. They developed a drug, which was tested on mice and the mice were successfully able to retrieve the cell functions. The successful development of such researches is expected to propel the global DNA repair drug market growth.

 

Global DNA Repair Drugs Market Restraints

 

Failure of drugs in late stages of clinical trials has hampered the global DNA repair drugs market growth. For instance, in April 2017, Veliparib, a product by AbbVie was withdrawn from both the clinical trial studies. One of the clinical trial study involved the drug’s efficacy on breast cancer and other for lung cancer. Veliparib was treated with a combination of chemotherapy for both, lung and breast cancer treatment. Both of the trials were withdrawn at its third phase. Such failures may hinder the global DNA repair drugs market growth.

 

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/2617

 

Global DNA Repair Drugs Market Key Players

 

Some of the major players operating in the global DNA repair drugs market include 4SC AG, Artios Pharma, Johnson & Johnson Service Inc., GlaxoSmithKline plc, Genentech, Inc., Sierra Oncology Inc., AstraZeneca, Karyopharm Therapeutics, Jiangsu Hengrui Medicine Co., Ltd., and Merck KGaA.

 

Global DNA Repair Drugs Market Taxonomy

 

The global DNA repair drugs market is segmented on the basis of drug, application, distribution channels, and regions.

 

By Drug

 

Niraparib (Zejula)

Olaparib (Lynparza)

Rucaparib (Rubraca)

Talazoparib (Talzenna)

Others

 

By Application

 

Ovarian cancer

Fallopian tube cancer

Peritoneal cancer

Breast cancer

Gastric cancer

 

By Distribution Channel

 

Hospital pharmacies

Retail pharmacies

Online pharmacies

 

By Region

 

North America

Latin America

Europe

Asia Pacific

Middle East

Africa

 

About Coherent Market Insights

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

 

Contact Us

 

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com